Trial reportInternational urology and nephrology2025
Effect of intravenous mannitol on renal function in patients undergoing laparoscopic nephron-sparing surgery: a randomized, double-blinded trial.
Trial report in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The effect of preemptive intravenous paracetamol-mannitol on postoperative analgesia and quality of recovery in elderly patients undergoing total hip arthroplasty.BMC anesthesiology · 2026Trial
- Beyond eGFR: critical appraisal of mannitol use in nephron- sparing surgery.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMannitol is often used as a renoprotective agent in nephron-sparing surgery (NSS) prior to renal vessel clamping. Although there is some recent evidence questioning its role, these studies used a fixed dose of mannitol and studied a heterogeneous group that included both laparoscopic and open NSS. This trial aimed to investigate whether renal-functional outcomes in patients undergoing laparoscopic NSS are equivalent in patients receiving weight-based mannitol and those administered placebo. MATERIALS AND
methodsIn this prospective, randomized, double-blinded, placebo-controlled trial, 100 patients who underwent laparoscopic NSS with an estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m2 were randomized to receive either weight-based mannitol (0.25 g/kg) or placebo (0.9% saline) 30 min prior to vessel clamping. Standardized anesthesia and fluid management protocols were followed. A predefined equivalence margin of 8 units of eGFR was used to define equivalence between the groups. The primary outcome was the difference in eGFR between the two groups at 6 months after surgery. The secondary outcomes were the difference in eGFR on days 2 and 10, blood loss, and complications between groups.
resultsBaseline characteristics were comparable between the groups. The mean difference in eGFR of the two groups at 6 months from baseline was 2.25 (95%CI - 1.9, 6.4), which was within the margin for equivalence. Similarly, the mean difference (95% CI) for eGFR at day 2 and day 10 from the baseline was 0.58 (95% CI - 5.5, 6.6) and -0.38 (95%CI - 4.9, 4.1), respectively, suggesting equivalence between the groups. Complication rates were comparable between the two groups.
conclusionsIntraoperative mannitol administration was equivalent to placebo for renal-functional outcomes (eGFR) of patients undergoing laparoscopic NSS suggesting that this practice can be discontinued.
Indexed as
Identifiers
40514624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.